ALKERMES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.49 USD | -0.89% |
|
-0.41% | -11.72% |
| May. 02 | UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating | MT |
| May. 01 | Alkermes's Q1 Earnings, Revenue Grow But Miss Street View | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 1.5B | Sales 2025 * | 1.51B | Capitalization | 4.18B |
|---|---|---|---|---|---|
| Net income 2024 * | 336M | Net income 2025 * | 350M | EV / Sales 2024 * | 2.34 x |
| Net cash position 2024 * | 663M | Net cash position 2025 * | 1.03B | EV / Sales 2025 * | 2.09 x |
| P/E ratio 2024 * |
12.8
x | P/E ratio 2025 * |
12.7
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alkermes plc
More recommendations
More press releases
| 1 day | +2.74% | ||
| 1 week | +2.53% | ||
| Current month | +0.69% | ||
| 1 month | +1.19% | ||
| 3 months | -9.25% | ||
| 6 months | +3.04% | ||
| Current year | -10.92% |
1 week
23.88
24.75
1 month
23.2625.26
Current year
23.2632.88
1 year
22.0133.71
3 years
21.2433.71
5 years
11.9833.71
10 years
11.9880.71
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Blair Jackson
DFI | Director of Finance/CFO | 51 | 98-12-31 |
Shane Cooke
PSD | President | 61 | 11-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Nancy Snyderman
BRD | Director/Board Member | 72 | 16-05-25 |
Brian McKeon
BRD | Director/Board Member | 61 | 20-12-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.32% | 254 M€ | +11.45% | - | |
| 2.65% | 1 M€ | -2.17% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 24.49 | -0.89% | 1 266 564 |
| 24-05-13 | 24.71 | +2.74% | 1,290,892 |
| 24-05-10 | 24.05 | -0.87% | 1,001,642 |
| 24-05-09 | 24.26 | +0.66% | 1,013,536 |
| 24-05-08 | 24.1 | -1.99% | 1,096,635 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotes
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Calendar
2024-05-31
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
24.71
USD
Average target price
33.82
USD
Spread / Average Target
+36.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.92% | 4.18B | |
| +26.37% | 48.16B | |
| -1.01% | 41.73B | |
| +44.87% | 41.03B | |
| -5.31% | 28.77B | |
| +9.34% | 25.59B | |
| -21.69% | 18.96B | |
| +6.23% | 12.92B | |
| +26.99% | 12.03B | |
| -3.38% | 11.77B |
- Stock Market
- Equities
- ALKS Stock
